First, while its clinical impact is not known, pioglitazone has the potential to enhance ACE2 expression in the liver, adipose tissue and skeletal muscle (37, 38), suggesting that the use of thiazolidinediones may affect not only the prevalence of COVID-19 but the mortality from the disease. Here, ACE2 is linked to COVID-19.